Program
CCR8 Inhibitor IPG7236
Also written as “IPG7236”, “IPG7236- Single ascending dose” and “IPG7236- Multiple ascending dose”.
Its studies are mostly in Dermatitis, Atopic, led by Nanjing Immunophage Biotech.
Furthest: phase 2, since Nov 21, 20213 company-led studies, 1 open or runningNext primary completion: Dec 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Immunophage Biotech | 31 open or running | phase 2since Nov 21, 2021 | Nov 21, 2021 | Dec 30, 2028phase 2 · NCT07508761 |
Also a collaborator on its studies: Novotech (Australia) Pty.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2021First study: phase 2 study in Safety IssuesFirst studyNCT05142592 · 34 enrolled · United States, China
- Mar 17, 2022Phase 1 study in Dermatitis, AtopicNCT05288543 · 63 enrolled · Australia
- Mar 23, 2026Phase 2 study in Advanced Solid TumorNCT07508761 · 52 planned · China
Ahead
- Dec 30, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT07508761
TargetBeta
CCR8 →read by rule
“An orally bioavailable inhibitor of C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule
Other programs on CCR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cafelkibart | Sino Biopharmaceutical | phase 3 | 7 |
| denikitugrule | Gilead Sciences | phase 2 | 3 |
| imzokitug | Bristol-Myers Squibb | phase 2 | 2 |
| Anti-CCR8 Antibody-drug Conjugate TAK-188rule | Takeda | phase 2 | 1 |
| Anti-CCR8 Monoclonal Antibody HC006rule | hc-biopharma-inc | phase 1 | 2 |
| azirkitug | AbbVie | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07508761Advanced Solid Tumor · China | 2 | Recruiting | Dec 30, 2028 | 52 |
| NCT05288543Dermatitis, Atopic · Australia | 1 | Terminated | Mar 31, 2023 | 63 |
| NCT05142592Safety Issues · United States, China | 2 | Completed | Feb 8, 2026 | 34 |
How it is read
Names in the registry
- “IPG7236”, 2 entries
- “IPG7236- Single ascending dose”, 1 entry
- “IPG7236- Multiple ascending dose”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.